Welcome to our dedicated page for GENOMMA LAB INTL SAB ORD news (Ticker: GNMLF), a resource for investors and traders seeking the latest updates and insights on GENOMMA LAB INTL SAB ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GENOMMA LAB INTL SAB ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GENOMMA LAB INTL SAB ORD's position in the market.
Genomma Lab Internacional, S.A.B. de C.V. reported its financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include a net sales increase of 8.9% year-on-year, reaching Ps. 16.86 billion, and a gross profit rise of 6.6%, totaling Ps. 10.20 billion. The operating income grew by 7.1%, amounting to Ps. 3.26 billion, with an EBITDA increase of 8.1% and a margin of 20.6%. However, the fourth quarter showed a decline in gross profit margin to 57.1% from 63.0% year-over-year. The conference call for Q4 results is scheduled for February 23, 2023.
FAQ
What is the market cap of GENOMMA LAB INTL SAB ORD (GNMLF)?
